According to a commentary, the picture is not completely rosy as event rates in SENIOR were very low (166 [14%] of 1200), highlighting the issue of recruitment of elderly (>85 years) high-risk patients presenting with acute coronary syndrome and multiple comorbidities into randomised trials. It questions whether or not this trial is sufficient in its own right to recommend informal or formal change in guidelines. The commentators think not as this was a single trial with only two variables and a small number of patients with a median age of 81 years. They suggest however, that if an elderly patient at high bleeding risk is having PCI, then a drug-eluting stent (DES) might now be considered with the knowledge that a shorter duration of DAPT may not lead to more ischaemic events and will probably reduce the risk of bleeding. They acknowledge that whether or not the interventionist has enough evidence on the basis of this study to prospectively prescribe 1 month DAPT and DES for stable patients and 6 month DAPT and DES for patients with acute coronary syndrome is another question and probably cannot be answered. They add that if a stable patient receiving a DES has a bleed at 6 weeks or a patient with acute coronary syndrome receiving a DES has a bleed at 7 months, the interventionist could be reassured they could stop the DAPT.